The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2021 | Update from a phase 1 study of AMG 757 in SCLC
Sanjay Popat, BSc, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, UK, shares an update on a Phase I study of AMG 757 (NCT03319940) in patients with small cell lung cancer (SCLC). AMG 757 is a bispecific T-cell engager (BiTE) which simultaneously binds to delta-like ligand 3 (DLL3) on SCLC cells and CD3 on T-cells. 52 patients were enrolled on the study. 79% of patients reported treatment-related adverse events (AEs) of which 8% were grade 4 or above. Cytokine release syndrome occurred in 44% of patients. 14% of patients achieved a partial response (PR) according to modified RECIST 1.1 criteria and 24% of patients achieved stable disease. The median time to response was 1.8 months and the estimated duration of response was over six months in 83% of patients with a confirmed PR. This video was recorded at the virtual European Lung Cancer Congress (ELCC) 2021.
